A new year always brings new challenges, and there will be many challenges facing the pharmaceutical industry and policymakers in 2026 as Americans continue to clamor for affordable medicines that deliver relief and cures.
Meeting those challenges is no easy task, given the complexities of drug development, health care insurance, and a societal desire to ensure there is enough competition to achieve these goals.
This year is likely to present a large number of twists and turns, especially as the Trump administration tries to deliver on its oft-stated promise to lower the cost of medicines. Here are a few key issues to watch as that plays out:
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply